BACKGROUND/AIM: The aim of this study was to determine the importance of surgical treatment, utility of hormone receptor status and selected biomarkers in the prognosis of patients with liver metastases from breast cancer (BCLM). PATIENTS AND METHODS: Thirty female underwent surgery for BCLM between 1/2000 and 1/2019. RESULTS: The type of surgery (resection/radiofrequency ablation) had no impact on overall survival (OS) - (p=0.894). Having more than one BCLM (p=0.003), expression of human epidermal receptor 2 in metastases (p=0.034), as well as an elevated presurgical level of carbohydrate antigen 19-9 (p=0.017) and postsurgical thymidine kinase (p=0.034) were negative prognostics factor for recurrence-free survival. The factors affecting OS included the number of liver procedures (p=0.021), the degree of proliferative activity (p=0.008) and elevated postsurgical carcinoembryonic antigen level (p=0.038). CONCLUSION: The type of surgery had no impact on OS. Markers and hormonal status of liver metastases are important factors affecting prognosis.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Czech National Oncological Register Pilsen Czech Republic

Department of Immunochemistry Diagnostics Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Czech Republic

Department of Pathology Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Czech Republic

Department of Plastic Surgery Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Czech Republic

Department of Surgery Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Czech Republic

Zobrazit více v PubMed

Ruiz A, Wicherts DA, Sebagh M, Giacchetti S, Castro-Benitez C, van Hillegersberg R, Paule B, Castaing D, Morère J-F, Adam R. Predictive profile-nomogram for liver resection for breast cancer metastases: An aggressive approach with promising results. Ann Surg Oncol. 2017;24(2):535–545. doi: 10.1245/s10434-016-5522-7. PubMed DOI

Follana P, Barrière J, Chamorey E, Largillier R, Dadone B, Mari V, Hannoun-Levi JM, Marcy M, Flipo B, Ferrero J-M. Prognostic factors in 401 elderly women with metastatic breast cancer. Oncology. 2014;86(3):143–151. doi: 10.1159/000357781. PubMed DOI

Golse N, Adam R. Liver metastases from breast cancer: What role for surgery? indications and results. Clinical Breast Cancer. 2017;17(4):256–265. doi: 10.1016/j.clbc.2016.12.012. PubMed DOI

Treska V, Cerna M, Liska V, Treskova I, Narsanska A, Bruha J. Surgery for breast cancer liver metastases - factors determining results. Anticancer Res. 2014;34(3):1281–1286. PubMed

Treska V, Cerna M, Kydlicek T, Treskova I. Prognostic factors of breast cancer liver metastasis surgery. Arch Med Sci. 2015;11(3):683–685. doi: 10.5114/aoms.2015.52376. PubMed DOI PMC

Lubrano J, Roman H, Tarrab S, Resch B, Marpeau L, Scotté M. Liver resection for breast cancer metastasis: Does it improve survival. Surgery Today. 2008;38(4):293. doi: 10.1007/s00595-007-3617-2. PubMed DOI

Elias D, Maisonnette F, Druet-Cabanac M, Ouellet J-F, Guinebretiere J-M, Spielmann M, Delaloge S. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg. 2003;185(2):158–164. doi: 10.1016/S0002-9610(02)01204-7. PubMed DOI

Martinez SR, Young SE, Giuliano AE, Bilchik AJ. The utility of estrogen receptor, progesterone receptor, and HER-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. The Am J Surg. 2006;191(2):281–283. doi: 10.1016/j.amjsurg.2005.08.030. PubMed DOI

Caralt M, Bilbao I, Cortés J, Escartín A, Lázaro JL, Dopazo C, Olsina JJ, Balsells J, Charco R. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann Surg Oncol. 2008;15(10):2804. doi: 10.1245/s10434-008-0072-2. PubMed DOI

Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795. doi: 10.1200/JCO.2009.25.6529. PubMed DOI PMC

Hoefnagel LDC, van de Vijver MJ, van Slooten H-J, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EGE, van der Wall E, van Diest PJ. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12(5):R75. doi: 10.1186/bcr2645. PubMed DOI PMC

Liedtke C, Broglio K, Moulder S, Hsu L, Kau S-W, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953–1958. doi: 10.1093/annonc/mdp263. PubMed DOI PMC

Kerbel RS. Growth dominance of the metastatic cancer cell: Cellular and molecular aspects. Adv Cancer Res. 1990;55:87–132. doi: 10.1016/s0065-230x(08)60469-8. PubMed DOI

Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi O-P, Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57(8):1597–1604. PubMed

Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer. 2012;118(20):4929–4935. doi: 10.1002/cncr.27518. PubMed DOI

Adam R, Aloia T, Krissat J, Bralet M-P, Paule B, Giacchetti S, Delvart V, Azoulay D, Bismuth H, Castaing D. Is liver resection justified for patients with hepatic metastases from breast cancer. Ann Surg. 2006;244(6):897–908. doi: 10.1097/01.sla.0000246847.02058.1b. PubMed DOI PMC

Yoo TG, Cranshaw I, Broom R, Pandanaboyana S, Bartlett A. Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: Is there a survival benefit. Breast. 2017;32:162–172. doi: 10.1016/j.breast.2017.02.003. PubMed DOI

Ruiz A, Castro-Benitez C, Sebagh M, Giacchetti S, Castro-Santa E, Wicherts DA, van Hillegersberg R, Paule B, Castaing D, Morère J-F, Adam R. Repeat hepatectomy for breast cancer liver metastases. Ann Surg Oncol. 2015;22 Suppl 3:S1057–66. doi: 10.1245/s10434-015-4785-8. PubMed DOI

Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone metastasis prognostic factors in breast cancer. Breast Cancer. 2019;13:1178223419830978. doi: 10.1177/1178223419830978. PubMed DOI PMC

Liska V, Holubec L Jr, Treska V, Vrzalova J, Skalicky T, Sutnar A, Kormunda S, Bruha J, Vycital O, Finek J, Pesta M, Pecen L, Topolcan O. Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer. Anticancer Res. 2011;31(4):1447–1451. PubMed

Peng L, Zhang Z, Zhao D, Zhao J, Mao F, Sun Q. Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer: A retrospective analysis of 107 cases. Medicine. 2020;99(25):e20738. doi: 10.1097/MD.0000000000020738. PubMed DOI PMC

Brierley J, Gospodarowicz M, Wittekind C. Wiley Blackwell. 2017. TNM Classification of Malignant Tumours (Eighth Edition) pp. 154–159.

Hormone receptor conversion in metastatic breast cancer